10-Nov-2008 - QIAGEN N.V.

QIAGEN and Institute for Animal Health Enter Partnership in Bluetongue Testing

QIAGEN N.V. has announced that it has entered into a worldwide exclusive partnership with the Institute for Animal Health (IAH), a research and diagnostics institution for infectious diseases of farm animals. Pursuant to the agreement QIAGEN has licensed a novel molecular assay design for bluetongue, a viral disease among ruminants such as sheep and cattle. The cador BTV RT-PCR Kit, which was developed by the IAH, will be launched by QIAGEN in 2009 and further expand the company's veterinary testing portfolio.

Bluetongue is caused by the bluetongue virus (BTV). It mainly afflicts cattle and sheep which exhibit the highest morbidity and mortality rates reaching up to 70 percent. Since 1998, the disease has been rapidly spreading throughout Europe with outbreaks in most countries including the United Kingdom, Spain, Italy, Greece, Belgium, The Netherlands, Germany and France. In 2008 alone, 16 outbreaks of the disease have been registered across Europe. Currently authorities in the Netherlands and several other countries in Europe are struggling to contain outbreaks caused by a BTV type 8, previously only found in Central and South America, and Africa. The IAH estimates the potential economic impact of a major bluetongue outbreak to exceed € 600 million in the U.K. alone - resulting from increased mortality rates, losses in milk production, export and animal movement restrictions. Containment and therefore early detection tools are key to combat this disease.

"The combination of IAH know-how in bluetongue testing with QIAGEN's cutting-edge sample preparation and assay technologies creates a new powerful diagnostic tool to quickly identify infected animals and thus help to contain bluetongue outbreaks that are likely to occur in the future", said Prof. Peter Mertens, Head of the Arbovirus Research Group at the IAH. "Given QIAGEN's track record in molecular testing and its global reach, the company was a partner of choice to bring this technology to the international markets in order to fight this costly disease."

Facts, background information, dossiers
  • Belgium
  • Assay Designs
More about Qiagen
  • News

    QIAGEN expands Supervisory Board with appointment of a new member

    QIAGEN announced the appointment of Thomas Ebeling, a leading international executive with extensive experience in the healthcare, media and consumer goods industries, as a member of the Supervisory Board with immediate effect. Mr. Ebeling joins QIAGEN as part of a process launched by the S ... more

    QIAGEN fully acquires NeuMoDx Molecular

    QIAGEN N.V. announced the acquisition of the remaining 80.1% of diagnostics instruments company NeuMoDx Molecular, Inc. for $248 million in cash. The move rounds out QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology. The transaction was completed ... more

    Thermo Fisher Scientific and QIAGEN N.V. Agree on Amended Terms to Acquisition Agreement

    Thermo Fisher Scientific Inc. and QIAGEN N.V. announced that they have entered into an amendment to their acquisition agreement under which Thermo Fisher has commenced a tender offer to acquire all of the ordinary shares of QIAGEN. The amendment provides for an increase from the original of ... more

  • Companies

    QIAGEN GmbH

    QIAGEN is the leading provider of sample and assay technologies. Sample technologies are used to isolate DNA, RNA and proteins from any biological sample. Assay technologies are then used to make specific target biomolecules, such as the DNA of a specific virus, visible for subsequent analy ... more

    QIAGEN Instruments AG

    QIAGEN is the leading provider of sample and assay technologies. Sample technologies are used to isolate DNA, RNA and proteins from any biological sample. Assay technologies are then used to make specific target biomolecules, such as the DNA of a specific virus, visible for subsequent analy ... more

    QIAGEN N.V.

    QIAGEN is the leading provider of sample and assay technologies. Sample technologies are used to isolate DNA, RNA and proteins from any biological sample. Assay technologies are then used to make specific target biomolecules, such as the DNA of a specific virus, visible for subsequent analy ... more

More about Institute for Animal Health